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ABSTRACT 
 
Aim: Identification of risk factors predicting the development of death rattle 
 
Background: Respiratory tract secretions, often called death rattle, are among the most 
common symptoms in dying patients around the world. It is unknown whether death 
rattle causes distress in patients, but it has been globally reported that distress levels 
can be high in family members. Although there is a poor evidence base, treatment with 
antimuscarinic medication is standard practice worldwide and prompt intervention is 
recognised as crucial for effectiveness. The identification of risk factors for the 
development of death rattle would allow for targeted interventions. 
 
Design: A case ̶ control study was designed to retrospectively review two hundred 
consecutive medical records of mainly cancer patients who died in a hospice inpatient 
setting between 2009 and 2011. Fifteen potential risk factors including the original 
factors weight, smoking, final opioid dose and final Midazolam dose were investigated. 
 
Methods: Binary logistic regression to identify risk factors for death rattle 
development. 
 
Results: Univariate analysis showed death rattle was significantly associated with final 
Midazolam doses and final opioid doses, length of dying phase, and anticholinergic 
drug load in the pre-terminal phase. In the final logistic regression model only 
Midazolam was statistically significant, and only at final doses of 20 mg/24hrs or over 
(OR 3.81 CI 1.41-10.34). 
 
Conclusions: Dying patients with a requirement for a high dose of Midazolam have an 
increased likelihood of developing death rattle. 
 
Keywords: Midazolam, respiratory sounds, bronchial secretions, palliative care, 
terminal care, respiratory signs and symptoms, cholinergic antagonists, risk factors, 
death rattle, nursing 
 
Summary statement 
 
Why is this research or review needed? 
 In a systematic review and narrative analysis conducted by the authors no clear and 
undisputed risk factors were identified that predicted the development of death rattle in 
dying adults. 
 The identification of one or more risk factors predictive of death rattle development 
could lead to more targeted treatments and perhaps prophylaxis. 
 
What are the key findings? 
 Weight, smoking habits, final opioid doses and final Midazolam doses were 
investigated as potential risk factors for death rattle for the first time. Weight, smoking 
habits and final opioid doses were not found to be associated with the development of 
death rattle. 
 Midazolam given at the end of life was likely to increase the risk of death rattle, 
especially in dying adults who required increasing doses of Midazolam. 
 
How should the findings be used to influence policy/practice/research/education? 
 Clinicians should be mindful that dying adults with an increasing requirement for 
Midazolam are at higher risk of developing death rattle. 
 Midazolam is commonly used in end-of-life care worldwide and future research should 
investigate the relationship between the development of death rattle and the 
administration of Midazolam.
INTRODUCTION 
 
Death rattle is one of the most common symptoms in dying adults and predictive of impending 
death (Kehl & Kowalkowski, 2013). Death rattle has been defined as respiratory tract secretions 
that could not be cleared from oropharynx and trachea creating noisy ('rattling') respiration as 
the secretions oscillate with expiration and inspiration (Twycross & Lichter 1999). Worldwide, 
off-label use of antimuscarinic medication is standard treatment for death rattle (Lindqvist et 
al. 2013). However, prompt intervention is crucial, as antimuscarinics reduce secretion 
production, but do not remove secretions that have already pooled in the airways (Back et al., 
2001; Bennett et al., 2002). In addition, effectiveness of pharmacological treatments have been 
shown to be variable, making standardisation of treatment impossible which renders decision-
making difficult for both prescribers and nurses who commonly administer these drugs  
(Ahmedzai et al., 2015; Hirsch et al., 2012). It is unknown whether death rattle causes distress 
in patients, but distress levels can be high in family members (Shimizu et al. 2013). The 
identification of risk factors associated with the development of death rattle would allow for 
prophylactic treatments or at least enable early interventions (Kåss & Ellershaw, 2003; Sheehan 
et al., 2011; Wildiers et al., 2009). This article reports on a retrospective medical records review 
that investigated potential risk factors associated with the development of death rattle in a dying 
adult. 
 
Background 
 
Risk factors associated with the development of death rattle have been investigated by a number 
of research groups, either as their main objective or in supplementary examinations of cohort 
characteristics (Bennett, 1996; Campbell & Yarandi, 2013; Clark et al., 2008; Ellershaw et al., 
1995; Jakobsson et al., 2008; Kåss & Ellershaw, 2003; Morita et al., 2000, 2004, 2005; 
Nakajima et al., 2013; Pace et al., 2009; Sheehan et al., 2011; Wildiers & Menten, 2002; 
Yamaguchi et al., 2012). Many potential risk factors were identified in these studies, but there 
was no consensus regarding risk factors which may predict the development of death rattle in 
a dying adult. Table 1 illustrates the findings from these different researchers in chronological 
order which set the context for this current study. 
 
A systematic review was conducted to establish risk factors studied in relation to death rattle 
(Kolb et al., 2018). This paper describes the empirical investigation of the risk factors 
discovered in that review alongside other potential risk factors not previously examined. Table 
2 itemises all the potential risk factors suitable for investigation in this study. It details whether 
these potential risk factors have already been investigated or if they are new, and identifies the 
literature on which the new risk factors are based. Potential risk factors that have not been 
investigated before are weight, smoking history, and doses of opioids and Midazolam. The 
rationale for their inclusion is explained next. 
 
Weight 
Anorexia is a common problem in dying cancer patients and can often result in considerable 
weight loss and cachexia (Morita et al., 2004; Mondello et al., 2015). Alternatively, cancer 
modifying treatment, medication for symptom management and peripheral oedema can lead to 
substantial weight gain (Jakobsson et al., 2008; Schmitz, et al., 2014; Sturdza et al., 2008). It 
is known that obesity can cause pulmonary complications and worsen respiratory diseases 
(Koenig, 2001; Zammit et al., 2010). Therefore, weight was included as an original variable to 
be tested for association with death rattle. 
 
Smoking history 
Smoking is known to affect the respiratory system (Arcavi & Benowitz, 2004), and lung 
pathology was suggested to be a risk factor of death rattle (Kåss & Ellershaw, 2003). Kåss & 
Ellershaw (2003) recommended inclusion of a patient’s smoking history into future studies. 
They had found a significantly higher risk of death rattle in men and suggested that smoking 
might explain at last a part of the association. Hence, smoking history was included as an 
original variable. 
 
Medications 
First line drug treatment for death rattle are antimuscarinic medications, such as Hyoscine 
hydrobromide, Hyoscine butylbromide or Glycopyrronium bromide, a subgroup of 
anticholinergic medications. They antagonise acetylcholine and thereby block parasympathetic 
activity leading to decreased production of airway secretions (Prommer 2013). Other 
medications, especially medications given to the elderly and in palliative care, have 
anticholinergic properties causing side effects like dry mouth (Hoyle et al., 2012).  
 
The cumulative effect of one or more medications with anticholinergic properties is called 
anticholinergic load or burden (Fox et al. 2011). If medications given at the end of life 
contribute to the anticholinergic burden, then either they could provide protection from death 
rattle or, as Sheehan et al. (2011) found, might increase its risk. Although opioids and 
benzodiazepines in the form of Midazolam are only mildly anticholinergic, these are the 
medications most frequently given to patients at the end of life (Lindqvist et al., 2013). 
Therefore, doses of these two medication groups on day of death were included as original 
potential risk factors. 
 
 
THE STUDY 
 
Aim 
 
The aim of the study was to identify risk factors that are associated with the development of 
death rattle in a dying adult. 
 
Design 
 
Retrospective case ̶ control study study in which 200 medical records were reviewed. 
 
Participants 
 
A convenience sample of 200 consecutive medical records of patients who died in the inpatient 
unit of a hospice between 1 January 2009 and 2011 were selected for the study. Included were 
medical records of patients whose admission exceeded five days.  
 
The sample size was calculated according to MedCalc, a statistical software program (MedCalc,  
n.d.) that suggests the following calculation of minimum sample size in logistic regression 
based on the work of Peduzzi et al. (1996): 
 
“Let p be the smallest of the proportions of negative or positive cases in the population 
and k the number of covariates (the number of independent variables), then the 
minimum number of cases to include is: N = 10 k / p.” 
 
This means for this research assuming 25% of patients do not develop DR: N=10k /0.25=40k. 
Therefore, a minimum of 40 cases was required for each independent variable entered in the 
logistic regression.  
 
Data collection 
 
Data pertaining to the following potential risk factors associated with the development of death 
rattle were extracted from medical records and tabulated (see also Table 2): 
sex, age, weight, length of dying phase, length of stay, diagnosis, metastases, past medical 
history, fluid retention symptoms, smoking history, consciousness level, infection, regular 
opioid dose on day of death, regular Midazolam dose on day of death and anticholinergic load 
five days before death (pre-terminal phase). 
 
Table 3 shows the scale variables and the units in which they were measured, while Table 4 
displays the categorical variables with their respective categories. Based on the literature that 
implicated brain tumours because of their potential effect on the patient’s swallowing ability 
and diseases of the respiratory tract, the chosen categories for diagnosis and past medical history 
were illnesses potentially causing dysphagia, illnesses affecting breathing and other conditions. 
(Bennett, 1996; Ellershaw et al., 1995; Kåss & Ellershaw, 2003; Morita et al., 2004, 2000). 
Utilising the opioid conversion chart for equianalgesia from Oxford Desk Reference/Oncology 
all opioid doses were converted to subcutaneous Morphine Sulphate so that a consistent scale 
variable could be created (Laird & Fallon, 2011). The anticholinergic load scores of 
medications prescribed five days before death were determined using the anticholinergic drug 
scale (ADS) as presented by Lertxundi et al. (2012) and total scores calculated. 
 
Drug dosages were grouped into categories given that association with death rattle will have 
been likely to be non-linear. Choice of cut-off points was largely arbitrary, aimed at both 
providing reasonable numbers in each group for analysis whilst also giving indication of low 
(or no), medium and high drug dosages. Box 1 and box 2 below show numbers included in 
these categories. 
 
Ethical considerations 
 
Ethical approval was granted for this research project from the studied hospice on 04.09.2015 
(Ref: SH/KB) and from the associated University on 22.10.2015 (Ref: CC/ESB).  
 
Data analysis 
 
First, a pre-selection process was carried out: univariate analyses were applied to all fifteen 
variables using Pearson’s chi-square and Mann-Whitney U tests to determine associations 
between these variables and the outcome variable death rattle. Only variables that were 
statistically significant in this initial analysis became variables in the binary logistic regression 
analysis. The Statistical Package for the Social Sciences IBM SPSS Statistics 22 was used for 
data analysis. 
 
Validity, reliability and rigour 
 
A series of procedures were used to test the model regarding goodness-of-fit (Field, 2013). 
Besides the Hosmer and Lemeshaw goodness-of-fit test, Field (2013) and Pallant (2007) advise 
the examination of residuals to test how well the model fits regarding two aspects: firstly, which 
cases exert an undue influence on the model and secondly, for which cases the model does not 
fit. These residual tests were run with the logistic regression in SPSS. Finally, multi-collinearity 
diagnostics were performed. All test results confirmed a good model fit and absence of multi-
collinearity. 
 
RESULTS 
 
The age range of the studied patients was 41 to 93 years with a mean of 72 years (SD 11.56). 
Sex was equally distributed with 47% male (n=94) and 53% female patients (n=106). Only 
4.5% (n=9) had a non-malignant diagnosis. In this sample, 75.5% developed death rattle while 
24.5% did not. The results of the descriptive analyses of the data are included in Tables 3 and 
4.  
 
Table 5 shows the logistic regression models. The unadjusted odds ratios indicate that both 
midazolam and morphine were associated with an increased likelihood of death rattling 
occurring when not adjusted. In both cases, the increased odds were only statistically significant 
at higher dosages. Midazolam was associated with a fourfold increase at both 40-59 mg/24hrs 
(OR 1.47-14.82), with a similar increase with the administration of 40-59 mg/24hrs in the final 
day of life. A lower dosage of 1-19 mg/24hrs had no statistically significant increase in odds of 
death rattle occurring. 
 
Relative to those on doses of under 20 mg/24hrs of morphine in the final day of life, those 
receiving higher doses of morphine, more than 100 mg/24hrs, were estimated to be more than 
three times more likely to experience death rattle (OR 3.25 CI 1.34-7.83). Lower doses, between 
20 and 99 mg/24hrs, had no statistically significant association. 
With both drugs included in the model together, the association between morphine and death 
rattle was no longer significant regardless of dosage. For midazolam, higher doses remain 
statistically significant (OR 3.81 CI 1.405-10.336). 
 
DISCUSSION 
 
This study investigated whether there were any risk factors associated with the development of 
death rattle in a dying adult. Fifteen potential risk factors were isolated from 200 patients’ 
medical notes, some of which had not been researched before. Only variables that demonstrated 
a significance either in the Mann-Whitney U test or the Pearson’s Chi-square test were included 
in the regression analysis: length of dying phase, anticholinergic drug load on day five before 
death, final opioid dose, and final Midazolam dose. Only opioid and Midazolam doses were 
included in the regression model as the other variables did not contribute to the model.  
 
Midazolam was associated with death rattle at higher dosages. The apparent association 
between morphine (or other opioid) and death rattle was confounded by the administration of 
midazolam. With both drugs included in a single model, only midazolam remained significant. 
Estimates suggested that the association between higher dosages of midazolam and death rattle 
were high, with an odds ratio indicating those receiving the higher dosage to be more than three 
times as likely to experience a death rattle. However, despite the statistically significant results 
confidence intervals were wide given the relatively small numbers of people in the study and 
so estimates need to be treated with caution.  
 
Length of dying phase 
It has been suggested that a prolonged dying process might be associated with the development 
of death rattle (Kåss & Ellershaw, 2003). Duration of the dying process was assessed by 
researchers in different ways, either as length of stay (LOS) defined as survival time from 
admission to death or as duration of the terminal phase in hours. In this study LOS and terminal 
phase were both assessed. There was no association between LOS and death rattle found. The 
terminal phase was measured in days on an end-of-life pathway. Patients for whom this specific 
documentation was not used presumably died unexpectedly and fast. In these cases, length of 
dying phase was coded as zero days. Although length of dying phase was associated with death 
rattle according to the result of the Mann-Whitney-U test (p=0.013), it had no contributing 
value to the regression model and was excluded from it. 
 
Two studies had previously investigated associations between LOS and death rattle and their 
findings contradicted each other (Bennett, 1996; Morita et al., 2000). Kåss & Ellershaw (2003) 
measured the terminal phase in hours on an end-of-life pathway (<4 hours; 4-24 hours; 24-48 
hours; 48-72 hours) and found that the risk of death rattle development increased with a 
prolonged dying phase. However, this study did not find that length of time in the dying phase 
could predict death rattle. 
 
Anticholinergic drug load 
Sheehan et al. (2011) tested the association between the anticholinergic drug score at the 
beginning of the deteriorating phase and the need for antimuscarinic drugs. Contrary to their 
expectations that a high anticholinergic drug load might provide protection for the patient 
regarding death rattle, they found a significant positive association between death rattle and 
anticholinergic drug load. They found that with each unit increase in the anticholinergic drug 
score (ADS) the likelihood of death rattle doubled. Sheehan et al.’s (2011) results could not be 
confirmed in this study, but both studies found that anticholinergic properties of medication 
were not protective of death rattle for the patients. 
 
Final opioid dose 
In the univariate analysis, final opioid dose was associated with death rattle. However, it was 
not statistically significant in the regression analysis. The variable was retained, however, as 
single predictor models do not take interactions between variables into account (Field, 2013). 
Residual testing confirmed that the model had four influential cases with extremely high opioid 
doses but particularly low Midazolam doses. If excluded this would have produced even 
stronger result for Midazolam as a predictor. 
 
Final Midazolam dose 
With increasing doses of Midazolam, the odds ratio associated with  developing a death rattle 
increased. This is an original finding, as Midazolam doses have not been investigated before as 
potential risk factors for death rattle. Midazolam can be used for different symptoms in end-of-
life care, for breathlessness, agitation or delirium, as an anxiolytic sedative or as an 
anticonvulsant (HIS, 2014). It is prescribed in different doses depending on the indication. 
McNamara, et al. (1991) found that although the median dose was 30-35mg/24hrs of 
Midazolam for all indications, the range for muscle relaxation was 10-60mg/24hrs, for terminal 
agitated delirium 10-240mg/24hrs and for multifocal myoclonus or as prophylaxis against 
seizures 15-80mg/24hrs. More recently, Masman et al. (2015) showed that the median dose had 
increased to 60mg/24hrs since their previous assessment.  
 
It is possible that Midazolam did not cause death rattle in these cases. Despite the dose 
dependent relationship, the statistical model used cannot attribute causality and therefore 
further research will be needed. Also, Midazolam only explained 9% variance. Nevertheless, it 
is plausible to consider Midazolam as a contributing factor. It is believed that death rattle is 
caused by the inability to clear secretion from the airways due to a reduced swallow and cough 
reflex (Bennett, 1996). It is reasonable to speculate that Midazolam would make this situation 
worse. Midazolam is a muscle relaxant and given in the terminal phase might result in the 
relaxation of the throat thereby further decreasing the ability to clear secretion that gathered 
(Back et al., 2001). 
 
Limitations 
 
The retrospective nature of the study affected the quality of the data, particularly the 
measurement of weight, consciousness levels, smoking history and infection status. It also led 
to the exclusion of hydration levels at the outset as this was not recorded in the medical records. 
 
Further, doses of Midazolam and opioids were obtained from regular prescriptions. There is a 
possibility that results might have been different if ‘as required’ medication had been included. 
However, it was common practice in the study setting to include ‘as required’ medication from 
the previous 24 hours in the prescription of the continuous subcutaneous infusion for the next 
24 hours. This meant that the data on Midazolam doses reflected precisely the previous 24 
hours. As the day of death was of various lengths for individual patients the inclusion of prn 
medication from that time would have blurred the picture rather than increased the precision. 
 
Data was cross-sectional. It is very possible that those with a death rattle were more likely to 
receive midazolam. It may be that health care professionals were more likely to perceive a 
person to be in distress if they had a death rattle. If so, then the association will reflect that 
concern, rather than the drug causing the rattle. That explanation is notable given implications 
for drug use in palliative care. Further research is clearly needed. 
 
It could be argued that data from a prospective approach might have been of higher quality. 
However, as this study investigated a symptom that only occurs in the last days and hours of 
life, the cohort could be easily identified in a retrospective approach, including all patients who 
died in the studied time frame irrespective of their diagnosis or characteristics. This study could 
easily be replicated (Earle & Ayanian, 2006). 
 
The model only explained a little over 10% of the variation. Given that only two independent 
variables were included in the model, that is in itself a reasonably good fit. The other 90% of 
variation will likely have included factors relating to both the patient and those providing care. 
 
Finally, data collection was carried out in a hospice where most patients had a diagnosis of 
cancer and where very proactive symptom management was implemented. The generalisability 
to non-malignant diagnoses and other settings is not known. 
 
CONCLUSION 
 
This study investigated potential risk factors associated with the development of death rattle in 
adults at the end of life. It included analysis of risk factors that had not been investigated before. 
For the first time, medications given regularly in the terminal phase were investigated, and the 
Midazolam dose given on the last day of life was identified as a risk factor for the development 
of death rattle. This discovery is potentially important for practice and should be investigated 
further. 
 
Recommendations for practice 
 
Midazolam is a common medication used in in the last hours of life to treat a range of symptoms 
such as agitation, delirium or breathlessness (HIS, 2014). Scottish Palliative Care Guidelines 
(HIS, 2014) state that Midazolam should be titrated in 5 to 10mg steps. This study has shown 
that Midazolam dose was associated with the development of death rattle at higher doseages. 
Medical and nursing professionals are advised to closely monitor patients who fall into this risk 
group, especially when doses of Midazolam increase as the patient approaches death. This study 
has shown the odds ratio associated with developing a death rattle was only statistically 
significant with doses over 20 mg where there was a nearly four-fold increase in the likelihood. 
This is a clinically relevant finding given 60mg was the median dose (Masman et al., 2015).  
 
It is recommended that pharmacological treatment of death rattle is started as soon as possible 
to enable this to be reduced (Bennett et al., 2002; Back et al., 2001). Prophylactic treatment for 
death rattle is not recommended in the British national palliative care guidelines (Ahmedzai et 
al., 2015), but has been discussed in the literature (Kåss & Ellershaw, 2003; Hugel et al., 2006; 
Bradley et al., 2010). Future research could investigate the feasibility of prophylactically 
treating patients who fall into a risk group or investigate alternative pharmacological 
management to replace Midazolam for some indication. 
 
Recommendations for future research 
 
Risk factors 
As highlighted in the limitations, some imprecision in the data became apparent during data 
collection. While these variables (i.e. weight, consciousness levels, smoking history and 
infection status) were non-significant in this study, the affected variables could be risk factors 
for death rattle if investigated in a future project with more accurate data. 
 
Prophylactic treatment  
Following the identification of a risk group new treatment options for death rattle should be 
considered. The feasibility of prophylactic treatment could be gauged in future research. 
 
Midazolam 
Logistic regression is unable to determine a causal relationship between an increased likelihood 
of developing death rattle with an increase of the Midazolam dose. Future research should 
utilise a different study design to explore why Midazolam is administered to individual patients 
and whether there is a causal connection between the development of death rattle and this 
medication at differing doses. Finally, should Midazolam be shown to have a relationship with 
death rattle, future research should explore the efficacy of other medications in the treatments 
of symptoms at the end of life. 
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